Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients

NCT05858684 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT05858684
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05858684 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients
Lead sponsor
RenJi Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
May 11, 2023
Completion date
June 10, 2029
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

car-t cell therapy